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Abstract
Background:  We sought to elicit preference weights from parents for health states
corresponding to children with various levels of severity of atopic dermatitis. We also evaluated
the hypothesis that parents with children who had been diagnosed with atopic dermatitis would
assign different preferences to the health state scenarios compared with parents who did not have
a child with atopic dermatitis.
Methods: Subjects were parents of children aged 3 months to 18 years. The sample was derived
from the General Panel, Mommies Sub-Panel, and Chronic Illness Sub-Panel of Harris Interactive.
Participants rated health scenarios for atopic dermatitis, asthma, and eyeglasses on a visual analog
scale, imagining a child was experiencing the described state.
Results: A total of 3539 parents completed the survey. Twenty-nine percent had a child with a
history of atopic dermatitis. Mean preference scores for atopic dermatitis were as follows: mild, 91
(95% confidence interval [CI], 90.7 to 91.5); mild/moderate, 84 (95%CI, 83.5 to 84.4); moderate,
73 (95%CI, 72.5 to 73.6); moderate/severe, 61 (95%CI, 60.6 to 61.8); severe, 49 (95% CI, 48.7 to
50.1); asthma, 58 (95%CI, 57.4 to 58.8); and eyeglasses, 87(95%CI, 86.3 to 87.4).
Conclusions: Parents perceive that atopic dermatitis has a negative effect on quality of life that
increases with disease severity. Estimates of parents' preferences can provide physicians with
insight into the value that parents place on their children's treatment and can be used to evaluate
new medical therapies for atopic dermatitis.
Background
Atopic dermatitis is the most common of childhood skin
diseases, with a lifetime prevalence in children of 10% to
20% [1]. The disease is most common in industrialized
countries and among Caucasians and Asians [2]. Annual
total costs of treatment are estimated to range from $0.9
to 3.8 billion in the United States [3].
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Atopic dermatitis can have a negative impact on quality of
life by affecting psychosocial adjustment in children. Lap-
idus and Kerr [4] report that atopic dermatitis can cause
embarrassment, disrupt sporting activities in older chil-
dren, and interfere with employment opportunities
among adults. The disease can also have a negative impact
on families. Parents report feelings of guilt, exhaustion,
frustration, and helplessness [4-7]. Atopic dermatitis can
disrupt sleep in patients and their family members, and
parents can miss work or avoid outside work altogether to
care for a child with the disease [4,8]. Fivenson et al [9]
found that 50% of the total burden of illness of atopic der-
matitis is associated with lost productivity. Specifically,
they found that days lost from work and nights of sleep
lost were high among parents of young children with
atopic dermatitis [9]. These stresses take additional tolls
on familial relationships and are confounded in low-
income families, who often have minimal access to social
support mechanisms [4].
As the need to control increasing medical expenditures
continues to mount, formal economic evaluations are tak-
ing on a prominent role in assessing the value of new
medical therapies. To properly evaluate the impact of new
therapies for atopic dermatitis, patients' health-related
quality of life (HRQOL) must be considered. Although a
number of quality-of-life evaluations have been con-
ducted for adults and children affected with atopic derma-
titis [4,7,9-12], quality-of-life adjustments in cost-utility
analyses must be performed using preference weights.
Preference weights represent summary measures of
HRQOL associated with individual health states and are
necessary to calculate quality-adjusted life-years (QALYs)
for use in cost-utility analyses.
Although the prevalence of atopic dermatitis is highest in
children, the existing literature on patient preferences for
atopic dermatitis is limited to the adult population
[13,14]. However, eliciting preferences from children may
not be possible, because they lack the necessary language
skills and cognitive abilities to interpret and respond to
questions used to evaluate preferences. Evidence suggests
that proxy reports by parents may provide valid estimates
of HRQOL in children [15]. Therefore, our primary objec-
tive was to elicit preference weights from parents for
health states corresponding to children with various levels
of severity of atopic dermatitis. In addition, we evaluated
the hypothesis that parents with children who had been
diagnosed with atopic dermatitis would assign different
preferences to the health state scenarios compared with
parents who did not have a child with atopic dermatitis.
Methods
Preference assessment instrument
Patient preferences can be elicited using standard gamble
or time-tradeoff or direct rating methods such as a visual
analog scale. Because both the standard gamble and the
time-tradeoff exercises involve choices between two alter-
natives that involve a chance of death or longevity, we
believed it was unethical to ask parents to participate in
such exercises when children were the subjects. Therefore,
our choice for eliciting preferences was the rating scale.
We developed case scenarios for 5 levels of atopic derma-
titis severity – mild, mild/moderate, moderate, moderate/
severe, and severe. These severity levels were created by
combining the characteristics of an Investigator Global
Assessment (IGA) and the Eczema Area and Severity Index
(EASI) score [16]. Each scenario included descriptions of
erythema, infiltration and/or papulation, excoriation, and
lichenification, as well as location of body area affected
(Table 1). Efforts were made to ensure that the scenarios
were descriptive, explicit, nonjudgmental, and targeted to
an eighth-grade reading level. A medical artist developed
images to depict the descriptions of atopic dermatitis. We
also included 2 additional scenarios – one that described
wearing glasses and another that described suffering from
asthma – to compare the preferences for atopic dermatitis
health states to nondermatological health states. A pedia-
trician and a pediatric dermatologist reviewed the descrip-
tions and illustrations to ensure their validity and realism.
The scenarios were revised based on their comments.
Using cognitive interview techniques, we pilot-tested the
preference assessment instrument in a convenience sam-
ple of 20 parents of children who were being evaluated at
a local children's primary care clinic to assess patients'
understanding of the instrument and its instructions. The
instrument was further revised based on the results of the
pilot test.
Survey administration
A health state preference assessment asks subjects to make
judgments regarding the value of particular health states
[9]. Preferences for health states can be elicited from
patients with disease (or their family members), from
patients at risk for disease, or from the general public
[17,18]. We elected to develop preferences from family
members of children who currently had atopic dermatitis
or were at risk for the disease. To obtain responses from a
broad range of respondents in an efficient manner, we
recruited participants over the Internet. The sample was
derived from the General Panel, the Mommies Sub-Panel,
and the Chronic Illness Sub-Panel of Harris Interactive
(Rochester, NY), an international market research and
consulting firm. The General Panel is a multimillion-
member panel of respondents who register to participateBMC Pediatrics 2004, 4:21 http://www.biomedcentral.com/1471-2431/4/21
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in The Harris Poll online panel. The Mommies Sub-Panel
is a subpanel of respondents with children aged up to 2
years. The Chronic Illness Sub-Panel identifies respond-
ents (or household members) who have been diagnosed
with at least 1 of more than 44 chronic medical condi-
tions, including skin conditions. (The Mommies and
Chronic Illness Sub-Panels are part of The Harris Poll
online panel. Aside from parental and health status, their
members do not differ systematically from members of
the General Panel.).
Subjects were invited to participate in the survey from Feb-
ruary 12 through 14, 2002, and were asked to register at a
specific survey site. After consent was obtained online,
subjects completed the survey. Respondents were offered
the incentive of a chance to win one of five $100 prizes.
Respondents had to be adults with children aged 3
months to 18 years in order to be included in the study.
The study was approved by the institutional review board
of Duke University Medical Center.
Clinical data were based on self-report and included infor-
mation on diagnosis history and severity level. Specifi-
cally, respondents were asked if they had a child between
the ages of 3 months and 18 years who had ever been
diagnosed by a medical professional with atopic dermati-
tis. If they responded "yes," they were then asked to
describe the child's atopic dermatitis at its worst point by
selecting from the following response options: mild,
mild/moderate, moderate, moderate/severe, severe.
For the preference assessment, each respondent was given
the scenarios in the same order – mild through severe
atopic dermatitis, asthma, and glasses. Subjects were
Table 1: Scenario descriptions
Severity Scenario
Mild • The area looks like a light pink or white, dusty rash.
• It is affecting the cheeks.
• It is rarely itchy and your child scratches it only a few (about 3) times a day.
• There are only a few (about 3) slightly bumpy areas.
• There is no oozing or crusting.
• The skin is not dry or leathery.
• Sleep is rarely disrupted by itching.
Mild/Moderate • The area looks like a light pink or white, dusty rash.
• It is affecting the cheeks and the chin.
• It is somewhat itchy and your child scratches it about 5 times a day.
• There are about 5 slightly bumpy areas.
• There is no oozing or crusting.
• The skin is not dry or leathery.
• Sleep is somewhat disrupted by itching. Your child loses about 15 minutes of sleep each night because of scratching.
Moderate • The area looks like a dark pink rash.
• It is affecting the cheeks, the chin and the inside of the elbows.
• It is moderately itchy and your child scratches it often (about 15 times) during the day.
• There are about 7 moderately bumpy areas.
• There is no oozing or crusting.
• The skin is not dry or leathery.
• Sleep is disrupted by itching. Your child loses about 1 hour of sleep each night because of scratching.
Moderate/Severe • The area looks like a dark pink rash.
• It is affecting the cheeks, the chin and the inside of the elbows, and the back of the knees.
• It is itchy and your child scratches it often (about 30 times) during the day.
• There are about 10 moderately bumpy areas.
• There is some light oozing or crusting in one area.
• The skin is not dry or leathery.
• Sleep is disrupted by itching. Your child loses about 2 hours of sleep each night because of scratching.
Severe • The area looks like a red rash.
• It is affecting the cheeks, the chin and the inside of the elbows, and the back of the knees, and the trunk of the body.
• It is very itchy and your child scratches it scratching continuously throughout the day.
• There are numerous bumpy areas.
• There is oozing or crusting in some areas.
• The skin is dry and leathery in some areas.
• Sleep is disrupted by itching. Your child loses about 3 hours of sleep each night because of scratching.BMC Pediatrics 2004, 4:21 http://www.biomedcentral.com/1471-2431/4/21
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Table 2: Subject characteristics
Characteristic Responders (n = 3539) Nonresponders (n = 21974)
Age
Mean (SD) 40.6 (6.2) 41.0 (6.4)
Range 18–64 19–76
Female sex 3298 (93.2) 20263 (92.2)
Race/ethnicity*
White 3045 (89.7) 18507 (84.2)
Black/African-American 136 (4.0) 1098 (5.0)
Hispanic 79 (2.3) 703 (3.2)
Asian/Pacific Islander 21 (0.6) 171 (0.8)
Native American 38 (1.1) 316 (1.4)
Mixed/other 77 (2.3) 520 (2.4)
Unknown 0 559 (2.5)
Declined to answer 0 100 (0.5)
Education level†
Did not complete high school 55 (1.6) 706 (3.2)
High school degree 555 (15.7) 4366 (19.9)
Some college 1391 (39.3) 9074 (41.3)
College degree 991 (28.0) 5179 (23.6)
Some graduate school or degree 543 (15.4) 2568 (11.7)
Unknown 0 81 (0.4)
Annual household income‡
<$15000 107 (3.5) 868 (3.9)
$15000$24999 262 (8.6) 1983 (9.0)
$25000–$34999 410 (13.4) 2945 (13.4)
$35000–$49999 665 (21.7) 4177 (19.0)
$50000–$74999 806 (26.3) 5065 (23.0)
$75000–$99999 406 (13.3) 2003 (9.1)
$100000–$149999 220 (7.2) 1442 (6.6)
$150000–$199999 85 (2.8) 273 (1.2)
$200000–$249999 61 (2.0) 117 (0.5)
≥ $250000 16 (0.5) 103 (0.5)
Declined to answer 24 (0.8) 1 (0.0)
Unknown 0 2997 (13.6)
Employment status §
Employed full-time 1766 (80.0) 9070 (42.2)
Employed part-time 554 (15.7) 2355 (11.0)
Self-employed 281 (7.9) 1588 (7.4)
Not employed but looking for work 119 (3.4) 852 (4.0)
Not employed and not looking for work 70 (2.0) 588 (2.7)
Retired 40 (1.1) 258 (1.2)
Student 149 (4.2) 3071 (14.3)
Homemaker 974 (27.5) 3566 (16.6)
Disabled 0 138 (0.6)
Not sure 4 (0.1) 0
Declined to answer 4 (0.1) 0
Not applicable 0 0
Number of children in household
Mean (SD) 1.9 (1.0) 1.9 (1.2)
Range 0–9 0–15
Country of residence
Australia 2 (0.1) --
Canada 2 (0.1) --
United States 3535 (99.9) --
Values are reported as number (percentage) unless otherwise indicated.
*There were 143 missing responses for this variable.
† There were 4 missing responses for this variable.
‡ There were 477 missing responses for this variable.
§ Responses sum to more than 100% because respondents could select more than one answer. Nonresponders did not have this option. There 
were 488 missing responses for this variable.BMC Pediatrics 2004, 4:21 http://www.biomedcentral.com/1471-2431/4/21
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instructed to indicate on a scale ranging from 100 (perfect
health) to 0 (death) how good or bad they believed it
would be to be a child experiencing the scenario depicted.
Respondents recorded their values using a movable
pointer on the scale. Respondents whose Internet browser
software did not support the movable pointer entered
their numerical responses manually into a required field.
All 7 values were summarized at the end of the survey to
allow respondents to review and, if desired, revise their
ratings.
Data analysis
Descriptive statistics were used to describe the sample.
Because subjects provided responses across severity levels,
a repeated-measures analysis of variance was conducted
using polynomial contrasts for the within-subjects (sever-
ity) effect. A P value of ≤ .05 was used as the criterion for
statistical significance.
Results
Of the 28105 subjects contacted, 6131 (22%) responded.
Of the 6131 respondents, 3539 (57.7%) met the inclusion
criteria, consented to participate in the study, and com-
pleted the survey (Table 2). The mean age was 41 years;
93% of the subjects were women; and 90% were white.
Nonresponders were similar to responders with respect to
age, sex, and race/ethnicity. More than 98% of the sample
had at least a high school education, with 83% of
respondents completing at least some college courses.
Overall, the sample reflected moderate- to high-income
families, with 74% having an annual household income
of at least $35000. Thirty percent of the parents had a
child with atopic dermatitis, 55% had a child with
asthma, and 46% had a child who wore glasses.
Table 3 displays the characteristics of the children's atopic
dermatitis (n = 1017). Seventy-eight percent (n = 806) of
children were diagnosed more than a year ago. Sixteen
percent (n = 160) of the sample described their child's
atopic dermatitis as mild and 8% (n = 78) described their
child's atopic dermatitis as severe. Thirty-five percent (n =
357) of the sample reported their child's atopic dermatitis
under limited control or uncontrolled.
The mean values for all participants are presented in Table
4. Among the atopic dermatitis health states, there was a
progressive decline in respondents' preferences, with the
mildest state receiving the highest mean preference score
and the severe state receiving the lowest mean preference
score. On average, preferences for asthma were higher
than for severe atopic dermatitis but lower than moder-
ate/severe atopic dermatitis. Not surprisingly, wearing
glasses received a higher preference value than suffering
from asthma. Average preference values for the glasses
health state were ranked between the mild and mild/mod-
erate atopic dermatitis health states.
There was a significant effect of severity (F4,3391 = 3065.66;
P = .0001). The linear effect of severity (F1,3394 = 11454.90;
P < .0001) indicated that preference ratings significantly
decreased as the severity of the health states increased
(Figure 1). Furthermore, there was a significant main
effect for preferences reported by parents of children with
atopic dermatitis as compared to parents of children with-
out atopic dermatitis (F1,3394 = 8.10; P = .0045). Across all
health states, parents of children with atopic dermatitis
gave a slightly higher mean preference (72.85 [SD,
13.50]) compared to parents whose children did not have
atopic dermatitis (71.34 [SD, 14.19]) (Figure 1).
There was no significant severity by parent group interac-
tion (F4,3391 = 1.21; P = .31), indicating that the differences
across health states were the same for both parent groups.
Discussion
Our study evaluated preferences for 5 health states for
atopic dermatitis. The aggregate values for each health
state may be used for computing QALYs for new therapies
that treat atopic dermatitis or can be used to help physi-
cians make more informed decisions by considering par-
ents' perceptions of atopic dermatitis measured on a
continuum from perfect health to death. The differences
in average values across the 5 health states were generally
consistent, with mild at 91, mild/moderate at 84, moder-
ate at 73, moderate/severe at 61, and severe at 49.
Table 3: Disease characteristics for children with atopic 
dermatitis
Characteristic Subjects (n = 1017)
Time of diagnosis
≤ 1 month ago 119 (11.7)
7 months to <12 months ago 95 (9.3)
1 year to 5 years ago 467 (45.9)
> 5 years ago 336 (33.0)
Disease severity
Mild 160 (15.7)
Mild to Moderate 236 (23.2)
Moderate 277 (27.2)
Moderate to Severe 266 (26.2)
Severe 78 (7.7)
How well controlled?
Complete 206 (20.3)
Good control 409 (40.2)
Limited control 330 (32.4)
Uncontrolled 27 (2.6)
No treatment 45 (4.4)
Values are reported as number (percentage) unless otherwise 
indicated.BMC Pediatrics 2004, 4:21 http://www.biomedcentral.com/1471-2431/4/21
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Lundberg and colleagues [13] found that the mean
health-state utility using a rating scale for patients with
atopic dermatitis was 77, a value only slightly higher than
our average health-state utility of 73. This small discrep-
ancy could be explained by several factors. First, Lundberg
et al [13] asked adult patients to provide ratings for them-
selves, whereas our study asked parents to provide ratings
for children. Parents might feel that a given health state is
worse for their children than it would be for themselves.
Second, Lundberg et al [13] asked patients to provide a
rating for their current health state, whereas our study
asked parents to assign utilities to 5 varying levels of sever-
Table 4: Average health state preference values
Health State Mean Median 95% Confidence Interval
Mild atopic dermatitis 91.1 95.0 90.7–91.5
Mild/moderate atopic dermatitis 83.9 88.0 83.5–84.4
Moderate atopic dermatitis 73.1 76.0 72.5–73.6
Moderate/severe atopic dermatitis 61.2 63.0 60.6–61.8
Severe atopic dermatitis 49.4 50.0 48.7–50.1
Asthma 58.1 60.0 57.4–58.8
Wearing eyeglasses 86.8 94.0 86.3–87.4
Comparison of overall ratings, stratified by children with atopic dermatitis and children without atopic dermatitis Figure 1
Comparison of overall ratings, stratified by children with atopic dermatitis and children without atopic dermatitis
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ity of atopic dermatitis. The average severity level of Lun-
dberg et al's [13] sample might have been slightly lower
than the average severity among our 5 health states, mak-
ing the mean preference value slightly higher. By obtain-
ing preferences for varying levels of severity, our results
have greater applicability in various types of models for
decision making.
Although preference ratings were systematically higher
among parents of children with atopic dermatitis than
among parents whose children did not have atopic der-
matitis, the magnitude of the difference was small
(difference = 1.5). Research on adults who rate the health
states of other adults has suggested that people who have
experienced a particular health state are more likely to
assign a higher value to it than others who are asked to
imagine the health state [19-21]. The lack of a larger dif-
ference between the parent groups in our study could
indicate that parents evaluate health states of children the
same, regardless of whose children they are, because of a
general concern for all children. Regardless of the reason,
these results have important implications for the use of
community-based preference weights, as opposed to
patient-based (or parent-based) weights, in preference-
weighted decision analyses. For this limited therapeutic
domain, our study shows that parents in the general com-
munity would supply approximately the same preferences
as parents whose children suffer the condition under
study. Future research should consider whether this con-
sistency holds for other serious childhood diseases, such
as pediatric cancer.
Our study has several limitations. First, by using the Inter-
net, respondents did not have an opportunity to ask ques-
tions if they did not understand what they were being
asked to do. However, we feel that this limitation was neg-
ligible, because the instrument was pilot-tested using in-
person interviews, and the very large majority of
responses were ranked appropriately (eg, mild ranked
higher than severe). Secondly, there may be a sample bias
in using the Harris Interactive database. Our sample
reflected a predominately white, female cohort from a
high socioeconomic class and may present generalizabil-
ity issues. However, we received responses from 351
(14%) nonwhite respondents and 779 (22%) responses
from participants with an annual household income of
less than $35000, providing a sufficient number of
responses to test for differences by race/ethnicity and
income level. Further research will be needed to corrobo-
rate our findings using a population-based sample. Third,
since these data are self-reported, some parents may have
misclassified their children as having or not having atopic
dermatitis, potentially biasing our results. Fourth, it is
unclear whether physician assessment of severity would
correspond with the severity levels that we assigned to the
health states. However, physicians could evaluate the
descriptions provided to judge whether their assessments
are consistent. Finally, people enrolled in the Harris Inter-
active database are computer users who may be more
motivated to participate in a survey than the general pop-
ulation. It is unclear how or in what direction these sam-
ple biases might affect the results of our analyses.
We had an apparent response rate of 22%. Harris Interac-
tive generally achieves a 15% to 20% response rate when
using the Chronic Illness Sub-Panel. While our response
rate was higher than Harris' average response rate, possi-
ble reasons for why the response was low could be attrib-
uted to the nature of the study design. First, because
subjects were contacted by e-mail, it is possible that some
subjects did not open the e-mail message until after the
survey deadline. Second, Harris Interactive panel mem-
bers agree to be notified about survey opportunities, but
do not agree to participate in each survey. Since the char-
acteristics of responders and nonresponders did not dif-
fer, we have no reason to believe that nonresponse bias is
exerting a substantial influence on our results.
Conclusions
The results of this analysis clarify the values that parents of
children with atopic dermatitis assign to different atopic
dermatitis health states. These assigned values, relative to
the comparison states, clearly demonstrate the perceived
burden of atopic dermatitis by parents of children suffer-
ing from the disease. Understanding the preferences for
atopic dermatitis can provide physicians insight into the
value that parents place on treatments for their child's
disease and in evaluating the cost-effectiveness of thera-
pies for atopic dermatitis.
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